PaclitaxelRecent, repeatedEvidence- NCT07902999 · Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase 3 · live · background · “Paclitaxel injection” · registered Oct 2026
- NCT07652515 · GlaxoSmithKline · Phase 4 · live · background · “Paclitaxel” · registered Jun 2026
- NCT07286331 · GlaxoSmithKline · Phase 3 · live · comparator · “Paclitaxel” · registered Dec 2025
- NCT07044336 · AstraZeneca · Phase 3 · live · comparator · “Paclitaxel” · registered Jun 2025
- NCT06952504 · Merck & Co., Inc · Phase 3 · live · background · “Paclitaxel” · registered Apr 2025
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 1216 studies | 1320 studies | background 16 · comparator 13 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07902999 · Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin injection” · registered Oct 2026
- NCT07652515 · GlaxoSmithKline · Phase 4 · live · background · “Carboplatin” · registered Jun 2026
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT06952504 · Merck & Co., Inc · Phase 3 · live · background · “Carboplatin” · registered Apr 2025
- NCT06989112 · AstraZeneca · Phase 3 · live · comparator · “Carboplatin” · registered Mar 2025
| Eli Lilly and Company16% of its industry studies | 1114 studies | 1218 studies | background 18 · comparator 5 |
DoxorubicinRecent, repeatedEvidence- NCT07286331 · GlaxoSmithKline · Phase 3 · live · comparator · “Doxorubicin” · registered Dec 2025
- NCT07044336 · AstraZeneca · Phase 3 · live · comparator · “Doxorubicin” · registered Jun 2025
- NCT06584032 · HUTCHMED · Phase 3 · live · comparator · “doxorubicin” · registered Aug 2024
- NCT06486441 · Gilead Sciences · Phase 3 · live · comparator · “Doxorubicin” · registered Jun 2024
- NCT06340568 · BioNTech SE · Phase 3 · live · comparator · “Doxorubicin” · registered Mar 2024
| Hoffmann-La Roche10% of its industry studiesUS: off-patent, 14 generics marketed | 77 studies | 77 studies | comparator 9 · background 2 |
pembrolizumabRecent, repeatedEvidence- NCT07684599 · GlaxoSmithKline · Phase 3 · live · background · “Pembrolizumab” · registered Jun 2026
- NCT07578649 · Pfizer · Phase 3 · live · comparator · “Pembrolizumab” · registered May 2026
- NCT07054567 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Jun 2025
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT06989112 · AstraZeneca · Phase 3 · live · comparator · “Pembrolizumab” · registered Mar 2025
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 68 studies | 79 studies | comparator 2 · background 10 |
DocetaxelRecent, repeatedEvidence- NCT06952504 · Merck & Co., Inc · Phase 3 · live · background · “Docetaxel” · registered Apr 2025
- NCT06989112 · AstraZeneca · Phase 3 · live · comparator · “Docetaxel” · registered Mar 2025
- NCT06340568 · BioNTech SE · Phase 3 · live · comparator · “Docetaxel” · registered Mar 2024
- NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
- NCT05481645 · Sino Biopharmaceutical Limited · Phase 2 · background · “Docetaxel injection” · registered Jul 2022
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 67 studies | 46 studies | background 7 · comparator 3 |
FulvestrantRecent, repeatedEvidence- NCT07811232 · Advenchen Pharmaceuticals, LLC. · Phase 2 · live · background · “Fulvestrant” · registered Aug 2026
- NCT07109726 · Terremoto Biosciences Inc. · Phase 2 · live · background · “Fulvestrant injection” · registered Jul 2025
- NCT06993844 · Ensem Therapeutics · Phase 2 · live · background · “ETX-636 dose escalation in combination with fulvestrant” · registered May 2025
- NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Fulvestrant” · registered Apr 2023
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Fulvestrant” · registered Mar 2023
| AstraZeneca70% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 1 generic authorized | 55 studies | 55 studies | background 5 |
BevacizumabRecent, repeatedEvidence- NCT07054567 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Bevacizumab” · registered Jun 2025
- NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “Bevacizumab” · registered May 2023
- NCT05797168 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Feb 2023
- NCT05579366 · Genmab · Phase 2 · live · background · “Bevacizumab” · registered Oct 2022
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Jul 2022
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 45 studies | 45 studies | background 6 |
Albumin-Bound PaclitaxelRecent, repeatedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
- NCT06906341 · Corcept Therapeutics · Phase 2 · live · background · “Nab-paclitaxel 80 mg/m^2” · registered Apr 2025
- NCT06132958 · Merck & Co., Inc · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Nov 2023
- NCT05383482 · Laekna Limited · Phase 2 · background · “Nab paclitaxel” · registered Apr 2022
| Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008) | 44 studies | 33 studies | background 3 · comparator 1 |
LetrozoleRecent, repeatedEvidence- NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Letrozole” · registered Apr 2023
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Letrozole” · registered Mar 2023
- NCT05705505 · Traws Pharma, Inc. · Phase 2 · live · background · “Letrozole 2.5mg” · registered Jan 2023
- NCT05712941 · EQRx International, Inc. · Phase 3 · background · “Letrozole 2.5mg” · registered Oct 2022
| Novartis52% of its industry studiesUS: off-patent, 6 generics marketed | 44 studies | 33 studies | background 4 |
GemcitabineRecent, repeatedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
- NCT05548296 · Acrivon Therapeutics · Phase 2 · live · background · “Gemcitabine” · registered Aug 2022
- NCT05481645 · Sino Biopharmaceutical Limited · Phase 2 · background · “Gemcitabine Hydrochloride Injection” · registered Jul 2022
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Gemcitabine” · registered Aug 2021
- NCT04657068 · Artios Pharma Ltd · Phase 2 · live · background · “Gemcitabine” · registered Dec 2020
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 33 studies | 33 studies | background 7 |
CisplatinRecent, repeatedEvidence- NCT06952504 · Merck & Co., Inc · Phase 3 · live · background · “Cisplatin” · registered Apr 2025
- NCT05489211 · AstraZeneca · Phase 2 · live · background · “Cisplatin” · registered Jul 2022
- NCT05173987 · Merck & Co., Inc · Phase 3 · live · comparator · “cisplatin” · registered Dec 2021
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Cisplatin” · registered Aug 2021
- NCT04634877 · Merck & Co., Inc · Phase 3 · live · background · “Cisplatin” · registered Nov 2020
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 23 studies | 24 studies | background 6 · comparator 1 |
Antineoplastic AgentsRecent, repeatedEvidence- NCT07022483 · Daiichi Sankyo · Phase 3 · live · comparator · “Chemotherapy” · registered Jun 2025
- NCT06475599 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Chemotherapy drug” · registered Jun 2024
- NCT00739830 · Merck & Co., Inc · Phase 2 · comparator · “chemotherapy” · registered Aug 2008
| — | 22 studies | 22 studies | comparator 3 |
PemetrexedRecent, repeatedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT06758557 · Huabo Biopharm Co., Ltd. · Phase 2 · live · background · “Pemetrexed” · registered Jan 2025
| Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized | 22 studies | 22 studies | background 2 |
palbociclibRecent, repeatedEvidence- NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Palbociclib” · registered Apr 2023
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Palbociclib” · registered Mar 2023
| Pfizer81% of its industry studiesUS: Pfizer (FDA 2015)EU: off-patent, 1 generic authorized | 22 studies | 22 studies | background 2 |
ribociclibRecent, repeatedEvidence- NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Ribociclib” · registered Apr 2023
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Ribociclib” · registered Mar 2023
| Novartis87% of its industry studiesUS: Novartis (FDA 2017)EU: Novartis (EMA 2017) | 22 studies | 22 studies | background 2 |